Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Is to assess whether tesaglitazar given as monotherapy is non-inferior to glibenclamide given as monotherapy during 52 weeks in improving glycaemic control in patients with type 2 diabetes as determined by the absolute change in glycosylated haemoglobin A1c (HbA1c), from baseline to the end of the randomized treatment period.
Critère d'inclusion
- Men or women who are >18 years of age or older at the enrolment visit (visit 1) diagnosed with type 2 diabetes and treated with diet alone or on treatment with a single oral anti diabetic agent or low doses of two agents